US11016106B2 - Polyclonal-monoclonal ELISA assay for detecting N-terminus pro-BNP - Google Patents
Polyclonal-monoclonal ELISA assay for detecting N-terminus pro-BNP Download PDFInfo
- Publication number
- US11016106B2 US11016106B2 US15/181,283 US201615181283A US11016106B2 US 11016106 B2 US11016106 B2 US 11016106B2 US 201615181283 A US201615181283 A US 201615181283A US 11016106 B2 US11016106 B2 US 11016106B2
- Authority
- US
- United States
- Prior art keywords
- probnp
- monoclonal antibodies
- kit
- antibodies
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7019—Ischaemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/545—Synthetic resin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/80—Antihypertensive peptides
Definitions
- This invention relates to an NT-proBNP protein ELISA assay procedure and test kit which is a specific and sensitive in vitro assay for measuring the concentration of NT-proBNP in bodily fluids, particularly human plasma.
- the invention particularly relates to an NT-proBNP protein ELISA assay having a particularly high diagnostic specificity, whereby the assay is particularly designed to be predictive of mortality as a result of congestive heart failure.
- B-type natriuretic peptide (Brain natriuretic peptide, BNP) belongs to the family of structurally similar, but genetically distinct natriuretic peptides (NPs) first described by de Bold et al. (de Bold A J. Heart atria granularity: effects of changes in water-electrolyte balance. Proc Soc Exp Biol Med 1979; 161:508-511; de Bold A J, Borenstein H B, Veress A T and Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci 1981; 28:89-94).
- the NPs possess potent diuretic, natriuretic and vasodilatory properties and have been reported as valuable diagnostic and prognostic markers in cardiovascular disease, particularly for patients in New York Heart Association (NYHA) classes I-IV congestive heart failure (CHF) (Boomsma F and van den Meiracker A H. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res 2001; 51:442-449).
- NYHA New York Heart Association
- CHF congestive heart failure
- the BNP gene encodes for a 108 amino acid residue precursor molecule, proBNP (Sequence ID No. 1). Prior to secretion by cardiomyocytes, cleavage of this prohormone results in the generation of bioactive BNP from the COOH terminus.
- proBNP Stemcell precursor molecule
- NT-PROBNP Immunoreactive Amino-Terminal Pro-Brain Natriuretic Peptide
- NP measurements may help effectively target patients within high risk heart failure groups (e.g. coronary artery disease, hypertension, diabetes, aged) who will require follow-up assessment and treatment (Hughes D, Talwar S, Squire I B, Davies J E and Ng L L.
- High risk heart failure groups e.g. coronary artery disease, hypertension, diabetes, aged
- NPs have been shown to have good prognostic value with regards to both morbidity and mortality in heart failure.
- Monitoring NP levels may also provide guidance in tailoring therapies to meet the required intensity of the individual patient and in monitoring therapeutic efficacy (Richards A M, Doughty R, Nicholls G, MacMahon S, Sharpe N, Murphy J, et al. Plasma N-Terminal Pro-Brain Natriuretic Peptide And Adrenomedullin. Prognostic Utility And Prediction Of Benefit From Carvedilol In Chronic Ischemic Left Ventricular Dysfunction.
- WO 93/24531 (U.S. Pat. No. 5,786,163) to Hall describes an immunological method of identifying N-terminal proBNP and the antibodies used for it. To obtain these antibodies single synthetically produced peptides from the sequence of N-terminal proBNP are used. The production of antibodies by means of peptide immunization is possible in principle but the affinity regarding the whole molecule generally is too low to reach the necessary sensitivity in a test procedure. In addition, there is a danger that when using peptides the antibodies obtained can, for example, identify the C-terminus of the peptide and can therefore only bind to this fragment of the whole molecule, thus resulting in antibodies which generally cannot bind to the whole molecule, or can do so to only a limited extent.
- WO 93/24531 an antibody against one single peptide derived from the N-terminal proBNP is produced. It is shown that the antibodies produced bind to the immunization peptide (amino acids 47-64) in the competitive test format. It is however not shown that the antibodies are able to bind to native N-terminal proBNP as a whole molecule in a sample. Additionally, the sandwich test described in WO 93/24531 in a sample cannot be performed as described since there was no appropriate standard material and no antibodies against two different epitopes.
- the competitive test performed in PCT 93/24531 suffers from the fact that only a very moderate competition is reached after 48 hours of incubation from which only a low detection limit of approx. 250 fmol/ml can be derived. This is neither sufficient for the differentiation of healthy individuals and patients suffering from heart failure nor for a differentiated classification of patient samples into the severity degrees of heart failure. In addition, the long incubation times of the competitive test are not acceptable for routine measurements of the samples in automated laboratories.
- Hunt et al. (Clinical Endocrinology 47 (1997), 287-296) also describes a competitive test for the detection of N-terminal proBNP. For this a complex extraction of the plasma sample is necessary before the measurement; this may lead to the destruction of the analyte and error measurements.
- the antiserum used is produced analogously to WO 93/24531 by immunization with a synthetic peptide—Hunt et al. produces the antiserum by immunization with the N-terminal proBNP amino acids 1-13 and the peptide of amino acids 1-21 is used as a standard. For this test long incubation times are necessary too. After an incubation of 24 hours a lower detection limit of 1.3 fmol/ml is reached.
- WO 00/45176 Method of Identifying N-Terminal proBNP, Karl et al., discloses monoclonal and polyclonal antibodies isolated via the use of a recombinant NT-proBNP immunogen. The reference suggests the formation of an assay using the disclosed antibodies as being specific for NT-proBNP in bodily fluids. As will be more fully described, a comparison of the area under the curve (AUC) of a plot of the Receiver Operated Characteristics (ROC) for this assay versus the assay of the instant invention indicates that the instant invention demonstrates superior diagnostic performance.
- AUC area under the curve
- ROC Receiver Operated Characteristics
- WO 00/35951 Natriuretic Peptide Fragments, is directed toward an assay for NT-proBNP utilizing two antibodies directed toward differing epitopes of the NT-proBNP sequence.
- This assay suffers from similar deficiencies as that of Hall (U.S. Pat. No. 5,786,163) in that the antibodies are raised against synthetic peptide fragments as the immunogen.
- the instantly disclosed NT-proBNP protein ELISA assay and test kit is a specific and sensitive in vitro assay that is capable of measuring the concentration of NT-proBNP in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like.
- bodily fluids non-limiting examples of which are blood, serum, plasma, urine and the like.
- the following examples and descriptions will exemplify the use of the assay in human plasma.
- antibody or antibodies includes polyclonal and monoclonal antibodies of any isotype (IgA, IgG, IgE, IgD, IgM), or an antigen-binding portion thereof, including but not limited to F(ab) and Fv fragments, single chain antibodies, chimeric antibodies, humanized antibodies, and a Fab expression library.
- IgA, IgG, IgE, IgD, IgM an antigen-binding portion thereof, including but not limited to F(ab) and Fv fragments, single chain antibodies, chimeric antibodies, humanized antibodies, and a Fab expression library.
- the NT-proBNP ELISA assay test employs the sandwich ELISA technique to measure circulating NT-proBNP in human plasma.
- recombinant human proBNP (or rhproBNP) was expressed and purified for use as an immunogen.
- Polyclonal antibodies (PAb) specific for amino acid sequences within proBNP (1-25, 26-51, 52-76 or 77-108) of Sequence ID No. 1 were subsequently purified from goat serum by sequential affinity purification.
- recombinant human NT-proBNP (or rhNT-proBNP) was expressed and purified.
- Monoclonals were produced from supernatants for use in an NT-proBNP ELISA in pairing with the instantly described Goat Polyclonal Antibodies.
- the monoclonals were biotinylated and used as a detector antibody to bind to the NT-proBNP protein bound to anti-NT-proBNP capture antibody, thus forming a sandwich.
- FIG. 1 illustrates the method of selection of NT-proBNP and target peptides starting from a pre-proBNP precursor protein
- FIG. 2 is an ROC curve for the goat polyclonal/6G11 monoclonal assay
- FIG. 3 is a box-plot of NT-proBNP levels in NYHA Class III and IV versus controls;
- FIG. 4 is a box-plot of NT-proBNP levels in control subjects, stratified by age
- FIG. 5 outlines the ELISA procedure for utilizing the goat polyclonal/6G11 monoclonal assay of the instant invention.
- the NT-proBNP ELISA assay test employs the sandwich ELISA technique to measure circulating NT-proBNP in human plasma.
- Microplate wells coated with goat polyclonal anti-NT-proBNP capture protein constitute the solid phase.
- Test subject plasma, standards and controls are added to the coated wells and incubated with incubation buffer. No sample extraction step is required.
- NT-proBNP protein is present in the test sample, it will be captured by NT-proBNP specific antibody coated on the wells.
- a monoclonal anti-NT-proBNP detector antibody is added to the wells. The detector antibody binds to the NT-proBNP protein, or immunogenic fragments thereof, e.g.
- polypeptide fragments which are recognized by said antibody, bound to anti-NT-proBNP capture antibody, thus forming a sandwich.
- a polyclonal donkey anti-mouse IgG labeled with horseradish peroxidase (HRP) is added to the wells.
- HRP horseradish peroxidase
- an enzyme substrate is added to the wells and incubated.
- An acidic solution is then added in order to stop the enzymatic reaction.
- the degree of enzymatic activity of immobilized HRP is determined by measuring the optical density of the oxidized enzymatic product in the wells at 450 nm. The absorbance at 450 nm is proportional to the amount of NT-proBNP in the test subject sample.
- a set of NT-proBNP protein standards is used to generate a standard curve of absorbance versus NT-proBNP concentration from which the NT-proBNP concentrations in test specimens and controls can be calculated. It is understood that detection of the immunoreaction may be accomplished via direct or indirect methods which are well-known in the art.
- ProBNP-pUC9 plasmid construct was obtained from Dr. Adolfo J. de Bold (Ottawa Heart Institute).
- the full-length rhproBNP open reading frame (ORF) was obtained by polymerase chain reaction (PCR) and subcloning into pET32c (NcoI/XhoI).
- the pET32c vector was modified by removing 81 nucleotides so that the final fusion protein would not contain the S-tag and enterokinase sites.
- the sequence at the N-terminus of the rhproBNP ORF consisted of thioredoxin and poly-histidine tags and a thrombin cleavage site. There was no extra sequence at the C-terminus.
- the protein was expressed in Escherichia coli BL21 (DE3) cells and the crude cellular extract was prepared in non-denaturing conditions. The subsequent affinity purification was completed by Ni-NTA chromatography following the supplier's recommendations. Prior to injections, endotoxin levels in the rhproBNP solutions were lowered to acceptable levels using a Detoxigel® endotoxin-removing resin following the supplier's recommendations.
- Goats (La Mancha or Toggenburg breed) were immunized with purified recombinant human full-length proBNP (rhproBNP).
- rhproBNP purified recombinant human full-length proBNP
- the titer of immunized goats was monitored routinely by screening serum using a half-sandwich ELISA technique.
- Polyclonal antibodies (PAb) specific for amino acid sequences within proBNP (1-25, 26-51, 52-76 or 77-108) of Sequence ID No. 1 were subsequently purified from goat serum by sequential affinity purification using cyanogen bromide activated sepharose-4B (Pharmacia) coupled, according to the supplier's recommendations, to the following proteins or peptide sequences:
- the purified polyclonal antibodies were dialyzed against 20 mM PBS, pH 7.4, concentrated by ultrafiltration and stored at ⁇ 20° C.
- recombinant human NT-proBNP (or rhNT-proBNP) was expressed and purified.
- a proBNP-pUC9 plasmid construct was obtained from Dr. Adolfo J. de Bold (Ottawa Heart Institute).
- the rhNT-proBNP ORF was obtained by PCR and subcloning into pET32c (NcoI/XhoI).
- the sequence at the N-terminus of the rhNT-proBNP ORF consisted of thioredoxin, poly-histidine, and S-tag tags, as well as thrombin and enterokinase cleavage sites.
- the protein was expressed in Escherichia coli BL21 (DE3) cells and the crude cellular extract was prepared in non-denaturing conditions. The subsequent affinity purification was completed by Ni-NTA chromatography following the supplier's recommendations.
- Monoclonal antibodies secreted by hybridoma cell lines herein designated as 6G11-F11-D12 and as 1C3-E11-H9 for use in a method of immunoassay, wherein said antibodies are specific to the polypeptide consisting of amino acids 1-25 of human N-terminal brain natriuretic factor BNP(1-25), were obtained from Dr. Adolfo J. De Bold. These monoclonals were produced from supernatants for use in an NT-proBNP ELISA in pairing with the instantly described Goat Polyclonal Antibodies, and are designated 6G11 and 1C3 respectively. These clones are the subject of U.S. Ser. No.
- Confluent hybridoma culture supernatants were added to 96-well microtiter plates (NUNC, MaxiSorp, GIBCO BRL) coated with donkey anti-mouse IgG (H+L) immunoglobulins (Jackson ImmunoResearch) at 2 ⁇ g/ml in 100 mM carbonate buffer, pH 9.6. Excess binding sites were blocked with bovine serum albumin (BSA) in PBS, pH 7.4. After washing the plate with wash buffer (PBS containing 0.05% (v/v) Tween 20), 50 ⁇ L of each culture supernatant containing monoclonal antibody was incubated on the plate. Following 1 hour incubation at 37° C.
- BSA bovine serum albumin
- 96-well microtiter plates were coated with goat polyclonal antibodies affinity purified against proBNP amino acid peptide sequences 1-25, 26-51, or 52-76 (Syn-X Pharma) at 1 ⁇ g/ml in 100 mM carbonate buffer, pH 9.6. Excess binding sites were blocked as for method (i). After washing with wash buffer, recombinant human proBNP (Syn-X Pharma) was added to the wells at concentrations of 3 ng/ml or 0 ng/ml and the plate incubated for 2 hours at RT on a shaker.
- the purified antibodies were retested as described above for screening of hybridoma supernatants, but for the fact that the purified monoclonal antibodies were appropriately diluted in 100 mM carbonate buffer, pH 9.6 and coated directly onto the plate for screening as captures, or appropriately diluted in PBS containing 0.5% (w/v) BSA for screening as detectors.
- Optimal ELISA specificity and sensitivity for recombinant human proBNP and recombinant human NT-proBNP were obtained using the combination of goat polyclonal antibody affinity purified against proBNP amino acid peptide sequence 26-51 as capture with MAb clone designate 6G11 as detector.
- FIG. 5 the procedure for carrying out the ELISA assay of the instant invention is set forth.
- an ELISA Test Kit is provided for the purpose of carrying out the above-outlined procedure.
- each vial contains 0.5 ml, except for the 0 pg/ml standard which contains 1.0 ml.
- the extra volume allows for diluting samples that have values greater than 3000 pg/ml, if retesting is desired.
- TMB 3, 3′, 5, 5′-tetramethylbenzidine
- the time between addition of samples, standards, and controls to the first well and the last well should not exceed 10 minutes.
- washing can be accomplished manually by repeatedly aspirating microwell contents and refilling each microwell with 340 ⁇ l of wash solution, three times.
- a computer program may be used for handling ELISA type data to evaluate the NT-proBNP concentrations in test subjects' plasma and controls.
- FIG. 2 The receiver operating characteristic (ROC) curve is displayed in FIG. 2 ; an area under the curve (AUC) of 0.974 was obtained, with a corresponding standard error (s.e.) of 0.008.
- AUC area under the curve
- the diagnostic sensitivity with respect to the heart failure subjects was 90.4% (with 189 out of 209 such subjects with NT-proBNP levels above the cutoff) and the diagnostic specificity with respect to the control subjects was 94.1% (with 95 out of 101 such subjects with NT-proBNP levels below the cutoff).
- Fischer et al. (Fischer Y, Filzmaier K, Stiegler H, Graf J, Fuhs S, Franke A, Janssens U and Gressner A M (2001). “Evaluation of a New, Rapid Bedside Test for Quantitative Determination of B-Type Natriuretic Peptide.” Clinical Chemistry 47 591-594.) gave performance data comparing the Triage BNP test to an NT-proBNP EIA assay from Roche Diagnostics with respect to 93 subjects with underlying cardiac disease and suspected heart failure.
- the instant assay would be expected to exhibit superior diagnostic performance.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
human IgG (Jackson ImmunoResearch) | |
mouse IgG (Jackson ImmunoResearch) | |
proBNP amino acid sequence #1-25 of | |
Sequence ID No. 1 | |
(H P L G S P G S A S D L E T S G L Q E Q | |
R N H L Q) | |
coupled to Keyhole Limpet Haemocyanin | |
(ADI Inc.) | |
OR | |
proBNP amino acid sequence #26-51 of | |
Sequence ID No. 1 | |
(G K L S E L Q V E Q T S L E P L Q E S P | |
R P T G V W) | |
coupled to Keyhole Limpet Haemocyanin | |
(ADI Inc.) | |
OR | |
proBNP amino acid sequence #52-76 of | |
Sequence ID No. 1 | |
(K S R E V A T E G I R G H R K M V L Y T | |
L R A P R) | |
coupled to Keyhole Limpet Haemocyanin | |
(ADI Inc.) | |
OR | |
proBNP amino acid sequence #77-108 of | |
Sequence ID No. 1 | |
(BNP-32, S P K M V Q G S G C F G R K M D | |
R I S S S S G L G C K V L R R H) | |
coupled to Keyhole Limpet Haemocyanin | |
(ADI Inc.) |
Standard Dose (pg/ml) | Mean OD 450 nm | ||
0 | 0.046 | ||
50 | 0.095 | ||
150 | 0.178 | ||
375 | 0.347 | ||
1500 | 1.161 | ||
3000 | 1.781 | ||
Note: | |||
These values should not be used in lieu of a standard curve, which should be prepared at the time of assay. |
Performance Characteristics
Claims (20)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/181,283 US11016106B2 (en) | 2002-11-18 | 2016-06-13 | Polyclonal-monoclonal ELISA assay for detecting N-terminus pro-BNP |
US17/324,685 US20220099687A1 (en) | 2002-11-18 | 2021-05-19 | Polyclonal-monoclonal elisa assay for detecting n-terminus pro-bnp |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/300,733 US20040096919A1 (en) | 2002-11-18 | 2002-11-18 | Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP |
US10/359,051 US20040096920A1 (en) | 2002-11-18 | 2003-02-04 | Polyclonal-monoclonal elisa assay for detecting n-terminus proBNP |
US11/375,432 US7527939B2 (en) | 2002-11-18 | 2006-03-13 | Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP |
US12/421,409 US20090325195A1 (en) | 2002-11-18 | 2009-04-09 | Polyclonal-monoclonal elisa assay for detecting n-terminus pro-bnp |
US13/236,447 US9371382B2 (en) | 2002-11-18 | 2011-09-19 | Polyclonal-monoclonal ELISA assay for detecting N-terminus pro-BNP |
US15/181,283 US11016106B2 (en) | 2002-11-18 | 2016-06-13 | Polyclonal-monoclonal ELISA assay for detecting N-terminus pro-BNP |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/236,447 Continuation US9371382B2 (en) | 2002-11-18 | 2011-09-19 | Polyclonal-monoclonal ELISA assay for detecting N-terminus pro-BNP |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/324,685 Continuation US20220099687A1 (en) | 2002-11-18 | 2021-05-19 | Polyclonal-monoclonal elisa assay for detecting n-terminus pro-bnp |
Publications (2)
Publication Number | Publication Date |
---|---|
US20170010288A1 US20170010288A1 (en) | 2017-01-12 |
US11016106B2 true US11016106B2 (en) | 2021-05-25 |
Family
ID=32328820
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/375,432 Expired - Lifetime US7527939B2 (en) | 2002-11-18 | 2006-03-13 | Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP |
US12/421,409 Abandoned US20090325195A1 (en) | 2002-11-18 | 2009-04-09 | Polyclonal-monoclonal elisa assay for detecting n-terminus pro-bnp |
US13/236,447 Expired - Lifetime US9371382B2 (en) | 2002-11-18 | 2011-09-19 | Polyclonal-monoclonal ELISA assay for detecting N-terminus pro-BNP |
US15/181,283 Expired - Lifetime US11016106B2 (en) | 2002-11-18 | 2016-06-13 | Polyclonal-monoclonal ELISA assay for detecting N-terminus pro-BNP |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/375,432 Expired - Lifetime US7527939B2 (en) | 2002-11-18 | 2006-03-13 | Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP |
US12/421,409 Abandoned US20090325195A1 (en) | 2002-11-18 | 2009-04-09 | Polyclonal-monoclonal elisa assay for detecting n-terminus pro-bnp |
US13/236,447 Expired - Lifetime US9371382B2 (en) | 2002-11-18 | 2011-09-19 | Polyclonal-monoclonal ELISA assay for detecting N-terminus pro-BNP |
Country Status (6)
Country | Link |
---|---|
US (4) | US7527939B2 (en) |
EP (1) | EP1562990B1 (en) |
JP (1) | JP4610025B2 (en) |
AU (1) | AU2003302087A1 (en) |
CA (1) | CA2511680A1 (en) |
WO (1) | WO2004046194A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220099687A1 (en) * | 2002-11-18 | 2022-03-31 | Nexus Dx, Inc. | Polyclonal-monoclonal elisa assay for detecting n-terminus pro-bnp |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1562990B1 (en) * | 2002-11-18 | 2010-07-21 | Syn X Pharma, Inc. | Polyclonal-monoclonal elisa assay for detecting n-terminus probnp |
DE10355731A1 (en) * | 2003-11-28 | 2005-06-30 | Roche Diagnostics Gmbh | Analytical sandwich test to determine NT-proBNP |
AU2005235635B2 (en) | 2004-04-21 | 2010-11-18 | Alexion Pharmaceuticals, Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
CA2511269A1 (en) * | 2004-07-07 | 2006-01-07 | F. Hoffmann-La Roche Ag | Multimarker panel based on p1gf for diabetes type 1 and 2 |
ES2316044T3 (en) * | 2005-01-24 | 2009-04-01 | F. Hoffmann-La Roche Ag | THE USE OF CARDIAC HORMONES TO EVALUATE A CARDIOVASCULAR RISK WITH REGARD TO THE ADMINISTRATION OF ANTI-INFLAMMATORY PHARMACES. |
EP2084544B1 (en) * | 2006-11-10 | 2011-07-06 | Hytest Ltd. | Stable standards for bnp immunoassays |
DE102007010834A1 (en) * | 2007-03-03 | 2008-09-04 | Brahms Aktiengesellschaft | Method for in-vitro diagnosis or risk classification or outcome prognosis of heart failure for New york heart association patient, involves utilizing determination of marker proatrial natriuretic peptide |
CN101230101B (en) * | 2008-01-25 | 2012-03-28 | 中国人民解放军第三军医大学 | Recombinant protein used as NT-proBNP immunodiagnosis reagent standard as well as preparation method and use thereof |
EP2499489B1 (en) * | 2009-11-13 | 2015-01-07 | BG Medicine, Inc. | Risk factors and prediction of myocardial infarction |
AU2011350066A1 (en) | 2010-12-27 | 2013-07-11 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
US20140256593A1 (en) * | 2011-11-22 | 2014-09-11 | University Of Maryland, Baltimore | Plasmonic substrates for metal-enhanced fluorescence based sensing, imaging and assays |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
JP6787894B2 (en) | 2014-12-05 | 2020-11-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Treatment of seizures with recombinant alkaline phosphatase |
JP6868561B2 (en) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | How to treat subjects with alkaline phosphatase deficiency |
US11352612B2 (en) | 2015-08-17 | 2022-06-07 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
EP3355904A4 (en) | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia |
US11400140B2 (en) | 2015-10-30 | 2022-08-02 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
JP2019513711A (en) | 2016-04-01 | 2019-05-30 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Treating muscle weakness with alkaline phosphatase |
EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
WO2017214130A1 (en) | 2016-06-06 | 2017-12-14 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
US11116821B2 (en) | 2016-08-18 | 2021-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
AU2018243320A1 (en) | 2017-03-31 | 2019-10-10 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (HPP) in adults and adolescents |
WO2019190752A1 (en) | 2018-03-30 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
CN112710852B (en) * | 2021-03-26 | 2021-08-03 | 上海美迪西生物医药股份有限公司 | GNP polypeptide detection kit and detection method |
US20230288436A1 (en) * | 2021-10-25 | 2023-09-14 | Bionote, Inc. | Antibodies binding specifically to nt-probnp and use thereof |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4610025Y1 (en) | 1966-06-20 | 1971-04-08 | ||
WO1989012069A1 (en) | 1988-05-31 | 1989-12-14 | California Biotechnology Inc. | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
WO1993024531A1 (en) | 1992-06-03 | 1993-12-09 | Medinnova Sf | Bnp antibody and immunoassay using it |
US5420016A (en) * | 1992-03-24 | 1995-05-30 | Serim Research Corporation | Test device and kit for detecting helicobacter pylori |
WO2000035951A1 (en) | 1998-12-12 | 2000-06-22 | The University Of Leicester | Natriuretic peptide fragments |
WO2000045176A2 (en) | 1999-01-29 | 2000-08-03 | Roche Diagnostics Gmbh | METHOD OF IDENTIFYING N-TERMINAL proBNP |
US6117644A (en) | 1998-06-04 | 2000-09-12 | Ottawa Heart Institute Research Corporation | Predicting and detecting cardiac allograft rejection |
US20040096919A1 (en) | 2002-11-18 | 2004-05-20 | Michelle Davey | Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP |
US20040096449A1 (en) | 2002-11-18 | 2004-05-20 | Debold Adolfo J. | Monoclonal antibodies against N-Terminus proBNP |
WO2004046194A2 (en) | 2002-11-18 | 2004-06-03 | Syn X Pharma, Inc. | Polyclonal-monoclonal elisa assay for detecting n-terminus probnp |
US6960472B2 (en) * | 2002-11-18 | 2005-11-01 | Ottawa Heart Institute Research Corporation | Monoclonal antibodies against N-Terminus proBNP |
-
2003
- 2003-11-17 EP EP03811319A patent/EP1562990B1/en not_active Expired - Lifetime
- 2003-11-17 CA CA002511680A patent/CA2511680A1/en not_active Abandoned
- 2003-11-17 JP JP2004570255A patent/JP4610025B2/en not_active Expired - Fee Related
- 2003-11-17 AU AU2003302087A patent/AU2003302087A1/en not_active Abandoned
- 2003-11-17 WO PCT/CA2003/001771 patent/WO2004046194A2/en active Application Filing
-
2006
- 2006-03-13 US US11/375,432 patent/US7527939B2/en not_active Expired - Lifetime
-
2009
- 2009-04-09 US US12/421,409 patent/US20090325195A1/en not_active Abandoned
-
2011
- 2011-09-19 US US13/236,447 patent/US9371382B2/en not_active Expired - Lifetime
-
2016
- 2016-06-13 US US15/181,283 patent/US11016106B2/en not_active Expired - Lifetime
Patent Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4610025Y1 (en) | 1966-06-20 | 1971-04-08 | ||
WO1989012069A1 (en) | 1988-05-31 | 1989-12-14 | California Biotechnology Inc. | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
US5420016A (en) * | 1992-03-24 | 1995-05-30 | Serim Research Corporation | Test device and kit for detecting helicobacter pylori |
WO1993024531A1 (en) | 1992-06-03 | 1993-12-09 | Medinnova Sf | Bnp antibody and immunoassay using it |
US5786163A (en) * | 1992-06-03 | 1998-07-28 | Medinnova Sf | BNP antibody and immunoassay using it |
US6117644A (en) | 1998-06-04 | 2000-09-12 | Ottawa Heart Institute Research Corporation | Predicting and detecting cardiac allograft rejection |
WO2000035951A1 (en) | 1998-12-12 | 2000-06-22 | The University Of Leicester | Natriuretic peptide fragments |
WO2000045176A2 (en) | 1999-01-29 | 2000-08-03 | Roche Diagnostics Gmbh | METHOD OF IDENTIFYING N-TERMINAL proBNP |
AU758562B2 (en) | 1999-01-29 | 2003-03-27 | Roche Diagnostics Gmbh | Method of identifying N-terminal proBNP |
US20070059767A1 (en) * | 1999-01-29 | 2007-03-15 | Roche Diagnostics Gmbh | Method of identifying N-terminal proBNP |
WO2004046194A2 (en) | 2002-11-18 | 2004-06-03 | Syn X Pharma, Inc. | Polyclonal-monoclonal elisa assay for detecting n-terminus probnp |
US20040096919A1 (en) | 2002-11-18 | 2004-05-20 | Michelle Davey | Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP |
US20040096449A1 (en) | 2002-11-18 | 2004-05-20 | Debold Adolfo J. | Monoclonal antibodies against N-Terminus proBNP |
EP1562990A2 (en) | 2002-11-18 | 2005-08-17 | Syn X Pharma, Inc. | Polyclonal-monoclonal elisa assay for detecting n-terminus probnp |
US6960472B2 (en) * | 2002-11-18 | 2005-11-01 | Ottawa Heart Institute Research Corporation | Monoclonal antibodies against N-Terminus proBNP |
US20060154321A1 (en) | 2002-11-18 | 2006-07-13 | Syn X Pharma, Inc. | Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP |
JP2006521535A (en) | 2002-11-18 | 2006-09-21 | シン.クス ファーマ、インコーポレイテッド | Polyclonal, monoclonal, and ELISA assay for detection of NT-proBNP |
US20040096920A1 (en) | 2002-11-18 | 2004-05-20 | Michelle Davey | Polyclonal-monoclonal elisa assay for detecting n-terminus proBNP |
US7527939B2 (en) * | 2002-11-18 | 2009-05-05 | Nanogen, Inc. | Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP |
EP2251356A2 (en) | 2002-11-18 | 2010-11-17 | Syn X Pharma, Inc. | Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP |
JP4610025B2 (en) | 2002-11-18 | 2011-01-12 | シン.クス ファーマ、インコーポレイテッド | Polyclonal monoclonal Elisa assay for NT-proBNP detection |
US9371382B2 (en) * | 2002-11-18 | 2016-06-21 | Nexus Dx, Inc. | Polyclonal-monoclonal ELISA assay for detecting N-terminus pro-BNP |
EP3061769A1 (en) | 2002-11-18 | 2016-08-31 | Nexus DX, Inc. | Polyclonal-monoclonal elisa assay for detecting n-terminus probnp |
EP3450457A1 (en) | 2002-11-18 | 2019-03-06 | Nexus DX, Inc. | Polyclonal-monoclonal elisa assay for detecting n-terminus probnp |
Non-Patent Citations (59)
Title |
---|
Anmari, A. et al., Bubble Nasal CPAP Manual, Riyadh Al-Kharj Hospital Programme Neonatal Intensive Care, 2005. |
Boomsma, F., Van Den Meiracker AH. Plasma Aand B-Type Natriuretic Peptides: Physiology Methodology and Clinical Use, Cardiovascular Research, vol. 51, pp. 442-449, 2001. |
Campbell, D.J., et al., Plasma Amino-Terminal Pro-Brain Natriuretic Peptide Levels in Subjects Presenting to the Emergency Department With Suspected Acute Coronary Syndrome: Possible Role in Selecting Patients for Follow Up?, Journal of Internal Medicine, vol. 31, pp. 211-219, 2001. |
Clerico, et al., "Measurement of Cardiac Natriuretic Hormones (Atrial Natriuretic Peptide, Brain Natriuretic Peptide, and Related Peptides) in Clinical Practice: The Need for a New Generation of Immunoassay Methods," Clinical Chemistry 46(10):1529-1534(2000). |
Communication pursuant to Article 94(3) EPC dated Dec. 17, 2019 in European Application No. 18186495.0 in 5 pages. |
Communication pursuant to Article 94(3) EPC dated Oct. 1, 2019 in European Application No. 18186495.0 in 4 pages. |
De Bold, A.J., et al., Borenstein HB; Veress AT; Sonnenberg H. A Rapid and Potent Natriuretic Response to Intravenous Injection of Atrial Myocardial Extracts in Rats, Life Sciences, vol. 28, pp. 89-94, 1981. |
De Bold, A.J., et al., Heart Atria Granularity: Effects of Changes in Water-Electrolyte Balance, Proceedings of the Society for Experimental Biology and Medicine, vol. 161, pp. 508-511, 1979. |
European Search Report and Opinion dated Aug. 1, 2011 in European Application EP10169301.8. |
European search report dated Jun. 9, 2016 in the European application 15203244.7. |
Extended European Search Report dated Nov. 28, 2018 in European Patent Application Number18186495.0. |
File History of U.S. Appl. No. 10/300,733, filed Nov. 18, 2002. |
File History of U.S. Appl. No. 10/359,051, filed Feb. 4, 2003. |
File History of U.S. Appl. No. 11/375,432, filed Mar. 13, 2006. |
File History of U.S. Appl. No. 12/421,409, filed Apr. 9, 2009. |
Fischer, et al. "Evaluation of a New, Rapid Bedside Test for Quantitative Determination of B-Type Natriuretic Peptide," Clinical Chemistry, 47 (3): 591-594 (2001). |
Hammerer-Lercher, A. et al., Head-To-Head Comparison of N-Terminal Pro-Brain Natriuretic Peptide, Brain Natriuretic Peptide and N-Terminal Pro-Atrial Natriuretic Peptide in Diagnosing Left Ventricular Dysfunction. Clinica Chimica Acta, vol. 310, pp. 193-197, 2001. |
Hanley, B. et al. A Method of Comparing the Areas Under Receiver Operating Characteristic Curves Derived from the Same Cases, Radiology, vol. 148, No. 3 pp. 839-843, 1983. |
Hanley, J., A. et al., The Meaning and Use of the Area Under a Receiver Operating Characteristic (ROC) Curve. Radiology, vol. 143, pp. 29-36, 1982. |
Hobbs, F., D., R. et al., Reliability of N-Terminal Pro-Brain Natriuretic Peptide Assay in Diagnosis of Heart Failure: Cohort Study in Representative and High Risk Community Populations, BMJ, vol. 324, pp. 1-5, 2002. |
Hughes, D. et al., An Immunoluminometric Assay for N-Terminal Pro-Brain Natriuretic Peptide: Development of a Test for Left Ventricular Dysfunction, Clinical Science, vol. 96, pp. 373-380, 1999. |
Hunt et al. Clin. Endocrinol. 47: 287 (1997). * |
Hunt P., J. et al., The Aminoterminal Portion of Probrain Natriuretic Peptide (Probnp) Circulates in Human Plasma, Biochemical and Biophysical Research Communications, vol. 214, No. 3, pp. 1175-1183, 1995. |
Hunt, et al. "Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment", Clinical Endocrinology, 47:287-296 (1997). |
Hunt, P.J., et al., Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment, Clinical Endocrinology, vol. 47, pp. 287-296, 1997. |
Hystad, M., E. et al., Regional Cardiac Expression and Concentration of Natriuretic Peptides in Patients With Severe Chronic Heart Failure, Acta Physiologica Scandinavica, vol. 171, pp. 395-403, 2001. |
International Preliminary Examination Report dated Mar. 3, 2005 in the International Application PCT/CA2003/001771. |
International Search Report dated Jun. 24, 2004 in the International Application PCT/CA2003/001771. |
Karl, et al."Development of a Novel, N-terminal-pro-BNP (NT-proBNP) Assay with a Low Detection Limit", Scand. J. Clin. Lab. Invest. 59 (Suppl. 230): 177-181 (1999). |
Luchner, A. et al., N-Terminal Pro-Brain Natriuretic Peptide After Myocardial Infarction a Marker of Cardio-Renal Function, Hypertension, vol. 39, pp. 99-104, 2002. |
Mair, J., et al., the Impact of Cardiac Natriuretic Peptide Determination on the Diagnosis and Management of Heart Failure, Clinical Chemistry and Laboratory Medicine, vol. 39, No. 7, pp. 571-588, 2001. |
Mcdonagh, T. A. et al., Biochemical Detection of Left-Ventricular Systolic Dysfunction, The Lancet, vol. 351, pp. 9-13, 1998. |
Mcdonagh, T., A. et al., Left Ventricular Dysfunction, Natriuretic Peptides, and Mortality in Urban Population, Heart, vol. 86, pp. 21-26, 2001. |
Nilsson, J., C. et al., Left Ventricular Remodeling in the First Year After Acute Myocardial Infarction and the Predictive Value of N-Terminal Pro Brain Natriuretic Peptide, American Heart Journal, vol. 143, No. 4, pp. 696-702, 2002. |
Notice of Allowance dated Dec. 30, 2008 in U.S. Appl. No. 11/375,432. |
Notice of Allowance dated Mar. 1, 2016 in U.S. Appl. No. 13/236,447. |
Notice of Allowance dated Sep. 2, 2008 in U.S. Appl. No. 11/375,432. |
Notice of Reasons for Denial, dated Oct. 22, 2015, in Japanese Application No. 2004-570255. |
Office Action dated Apr. 10, 2014 in U.S. Appl. No. 13/236,447. |
Office Action dated Dec. 3, 2015 in U.S. Appl. No. 13/236,447. |
Office Action dated Feb. 27, 2013 in U.S. Appl. No. 13/236,447. |
Office Action dated Jan. 11, 2008 in U.S. Appl. No. 11/375,432. |
Office Action dated Jun. 24, 2015 in U.S. Appl. No. 13/236,447. |
Office Action dated May 18, 2007 in U.S. Appl. No. 11/375,432. |
Office Action dated Nov. 3, 2014 in U.S. Appl. No. 13/236,447. |
Office Action dated Oct. 11, 2006 in U.S. Appl. No. 11/375,432. |
Office Action dated Sep. 4, 2013 in U.S. Appl. No. 13/236,447. |
Omland, T. et al., Plasma Cardiac Natriuretic Peptide Determination as a Screening Test for the Detection of Patients With Mild Left Ventricular Impairment, Heart, vol. 76, pp. 232-237, 1996. |
Richards, A., M. et al., Plasma N-Terminal Pro-Brain Natriuretic Peptide and Adrenomedullin. New Neurohormonal Predictors of Left Ventricular Function and Prognosis After Myocardial Infarction, Circulation, vol. 97, pp. 1921-1929, 1998. |
Richards, M., A. et al. Plasma N-Terminal Pro-Brain Natriuretic Peptide and Adrenomedullin. Prognostic Utility and Prediction of Benefit From Carvedilol in Chronic Ischemic Left Ventricular Dysfunction, Journal of the American College of Cardiology, vol. 37, No. 7, pp. 1781-1787, 2001. |
Sagnella, G., A., Measurement and Importance of Plasma Brian Natriuretic Peptide and Related Peptides, Annals of Clinical Biochemistry, vol. 38, pp. 83-93, 2001. |
Schulz, H. et al., Radioimmunoassay for N-Terminal Probrain Natriuretic Peptide in Human Plasma, Scandinavian Journal of Clinical and Laboratory Investigation, vol. 61, pp. 33-42, 2001. |
Selvais, P.L., et al., Cardiac Natriuretic Peptides for Diagnosis and Risk Stratification in Heart Failure: Influences of Left Ventricular Dysfunction and Coronary Artery Disease on Cardiac Hormonal Activation, European Journal of Clinical Investigation, vol. 28, pp. 636-642, 1998. |
Sudoh, et al."Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide", Biochemical and Biophysical Research Communications, 159(3):1427-1434 (1989). |
Talwar, S., Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina, Heart, vol. 84, pp. 421-424, 2000. |
Talwar, S., Plasma N-Terminal Pro-Brain Natriuretic Peptide and the ECG in the Assessment of Left-Ventricular Systolic Dysfunction in a High Risk Population, European Heart Journal, vol. 20, pp. 1736-1744, 1999. |
Triage® B Type Natriuretic Peptide (BNP) Test, Product Insert, Biosite Diagnostics Inc., 2001. Downloaded on Mar. 14, 2019. |
Troughton, R., W. et al., Treatment of Heart Failure Guided by Plasma Aminoterminal Brain Natriuretic Peptide (N-BNP) Concentrations, The Lancet, vol. 355, pp. 1126-1130, 2000. |
Written Opinion dated Dec. 3, 2004 in the International Application PCT/CA03/01771. |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220099687A1 (en) * | 2002-11-18 | 2022-03-31 | Nexus Dx, Inc. | Polyclonal-monoclonal elisa assay for detecting n-terminus pro-bnp |
Also Published As
Publication number | Publication date |
---|---|
US20170010288A1 (en) | 2017-01-12 |
US20090325195A1 (en) | 2009-12-31 |
JP4610025B2 (en) | 2011-01-12 |
EP1562990A2 (en) | 2005-08-17 |
JP2006521535A (en) | 2006-09-21 |
US20120107848A1 (en) | 2012-05-03 |
WO2004046194A2 (en) | 2004-06-03 |
US9371382B2 (en) | 2016-06-21 |
CA2511680A1 (en) | 2004-06-03 |
US7527939B2 (en) | 2009-05-05 |
WO2004046194A3 (en) | 2004-08-05 |
EP1562990B1 (en) | 2010-07-21 |
AU2003302087A1 (en) | 2004-06-15 |
US20060154321A1 (en) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220099687A1 (en) | Polyclonal-monoclonal elisa assay for detecting n-terminus pro-bnp | |
US11016106B2 (en) | Polyclonal-monoclonal ELISA assay for detecting N-terminus pro-BNP | |
JP5159324B2 (en) | Human ring specific BNP antibody | |
RU2315773C2 (en) | Specific antibodies for diagnosis of cardiac insufficiency | |
US20060211070A1 (en) | Polyclonal-polyclonal ELISA assay for detecting N-terminus-proBNP | |
JP2009538288A (en) | Antibodies and standards for use in NT-proBNP and proBNP immunoassays | |
JP4741485B2 (en) | Detection assay for atrial and brain natriuretic peptide prohormones | |
US5827674A (en) | Hybridoma producing a monoclonal antibody for N-peptide | |
US6960472B2 (en) | Monoclonal antibodies against N-Terminus proBNP | |
US20040096449A1 (en) | Monoclonal antibodies against N-Terminus proBNP |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DXCON, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FINANCIERE ELITECH SAS;REEL/FRAME:046478/0437 Effective date: 20090626 Owner name: FINANCIERE ELITECH SAS, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NANOGEN INC.;REEL/FRAME:046478/0001 Effective date: 20090513 Owner name: NEXUS DX, INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:DXCON, INC.;REEL/FRAME:045502/0065 Effective date: 20090709 Owner name: NANOGEN POINT OF CARE INC., CANADA Free format text: CHANGE OF NAME;ASSIGNOR:SYNX PHARMA INC.;REEL/FRAME:045501/0366 Effective date: 20060209 Owner name: SYN X PHARMA, INC., CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DAVEY, MICHELLE;JACKOWSKI, GEORGE;KUPCHAK, PETER;AND OTHERS;SIGNING DATES FROM 20031028 TO 20031030;REEL/FRAME:045091/0102 |
|
AS | Assignment |
Owner name: NANOGEN INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NANOGEN POINT OF CARE INC.;REEL/FRAME:048654/0033 Effective date: 20081105 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction |